BioTime stock is currently selling for $1.18 USD on the NYSE American exchange. At the time of writing, shares are down nearly 5%. Despite a rough few trading days, BTX stock has a consensus rating of “Buy” from six analysts.
So let’s check this out.
BioTime StockBioTime Inc (NYSE:BTX) is a clinical-stage biotechnology company developing treatments for several degenerative diseases. Headquartered in California, the company’s flagship products include OpRegen, a treatment aimed at macular degeneration of the eye, which is synonymous with the elderly, OPC1, which is a treatment for acute spinal cord ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.